Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing.
Jianli TaoDaniel E BauerRoberto ChiarlePublished in: Nature communications (2023)
CRISPR-Cas gene editing has revolutionized experimental molecular biology over the past decade and holds great promise for the treatment of human genetic diseases. Here we review the development of CRISPR-Cas9/Cas12/Cas13 nucleases, DNA base editors, prime editors, and RNA base editors, focusing on the assessment and improvement of their editing precision and safety, pushing the limit of editing specificity and efficiency. We summarize the capabilities and limitations of each CRISPR tool from DNA editing to RNA editing, and highlight the opportunities for future improvements and applications in basic research, as well as the therapeutic and clinical considerations for their use in patients.
Keyphrases
- crispr cas
- genome editing
- nucleic acid
- circulating tumor
- single molecule
- cell free
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- prognostic factors
- genome wide
- current status
- deep learning
- artificial intelligence
- patient reported outcomes
- patient reported
- pluripotent stem cells
- induced pluripotent stem cells
- replacement therapy